CClinicalTrials.gg
CompletedNCT05755243TISSUESENSORUpdated Sep 28, 2023

Human Subcutaneous Inflammatory Response to Glucose Sensors

An observational study in Inflammatory Response to Glucose Sensors, sponsored by Corporacion Parc Tauli. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Corporacion Parc Tauli · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to describe the inflammatory response to enzimatic glucose sensors after 10 days of use and to evaluate the relationship between the magnitude of the FBR (foreign body response) with the accuracy of the sensor (MARD)

Read the detailed description

Eighteen Type 1 DM patients are going to be included. Primary Objectives

  1. To define the intra-individual and inter-individual variability of the macrophage count around the sensor
  2. To assess whether there is a relationship between the number of macrophages, fibrosis and MARD of the MCG registry.

Secondary Objectives

To describe the histology of tissue response. This description will include:

  1. HE stain: cell types, arrangement, vascular structures, signs of hemorrhage-clot. Giemsa stain: mast cells. Masson's trichrome stain: str. vascular.
  2. Immunohistochemistry: Vascular assessment, characterization of macrophages

Each patient will have 1 glucose sensor inserted in the non-dominant arm. During the useful life of the sensor (10), a minimum of 4 capillary blood glucose determinations/day will be performed The sensor has a length of 8 mm and a diameter of 0.4 mm. All the necessary material will be provided, including a control diary to help the patient remember to carry out the self-control and set its time distribution.

On the last day of sensor use, it will be removed and a 4-mm punch skin biopsy will be performed 5 minutes later.

Tissue samples will be fixed in 4% formaldehyde solution, paraffin blocks made and sectioned. The resulting samples will be stained Semiquantitative determination of lymphocytes, neutrophils, mast cells, macrophages will be performed; fibrin, fibrosis, vascular proliferation and karyorrhexis

In all cases, a quantitative immunohistochemical study will be performed with x40 field counting with photographs and grid (Dako omnis with envision system) for:

Macrophages

The monitor-glucometer will be recovered for download and study of the record. The interstitial glucose - blood pairs will be made with those recorded but not used for callibration.

Glucose sensor values and insulin doses will be recover from tha medical application

02

Conditions studied

  • Inflammatory Response to Glucose Sensors

Keywords

  • Enzymatic glucose sensors, foreign body response
03

In context

Lead sponsor

Corporacion Parc Tauli is the lead sponsor of 163 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eighteen people diagnosed with type 1 diabetes and treated with closed-loop systems

Inclusion criteria

    1. Type 1 diabetes of more than 6 months duration, confirmed by positivity for Ab antiGAD 65 2. Be a regular user of a continuous glucose monitoring system 2. To Understand the proposed protocol and acceptance of participation.

Exclusion criteria

Exclusion Criteria:

  • Treatment with drugs that could potentially modify the inflammatory response during the 10 days prior to surgery (non-steroidal anti-inflammatory drugs or corticosteroids, antioxidants or platelet antiaggregants).
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
24 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Biopsy performed

    after 10 days of use, the sensor is removed and the biopsy performed

    Device: glucose sensor

Interventions

  • Deviceglucose sensor

    skin biopsy (punch)

06

What researchers measure

Primary outcomes

  1. Number of Macrophages sourronding the sensor

    Time frame: 10 days

  2. MARD (CGM record for 10 days)

    median absolute relative difference (BG- Sensor glucose)

    Time frame: 10 days

07

Study locations

1 site
  • Hospital Parc Tauli
    Sabadell, Barcelona 08208, Spain
08

References and documents

Publications

  • Rigla M, Pons B, Rebasa P, Luna A, Pozo FJ, Caixas A, Villaplana M, Subias D, Bella MR, Combalia N. Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy. Diabetes Technol Ther. 2018 Apr;20(4):296-302. doi: 10.1089/dia.2017.0321. Epub 2018 Feb 22. PubMed 29470128 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05755243
Lead sponsor
Corporacion Parc Tauli
Responsible party
Mercedes Rigla (Director of Department, Corporacion Parc Tauli) — Principal investigator
First posted
Mar 6, 2023
Start date
Jun 21, 2022
Primary completion
Jul 12, 2023
Completion
Sep 20, 2023
Last update
Sep 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion